Ivantis (United States)

Exploited vulnerabilities and zero-day exploits continue to increase in frequency and are expected to accelerate further. This paper evaluates the increase in exploited vulnerabilities and outlines the five most common challenges organisations encounter when remediating vulnerabilities quickly. By understanding the challenges organisations face, the paper identifies solutions and discusses improvements to help increase responsiveness and reduce exposure time. Some of the challenges are organisational and political. Others are more process and technical oriented. The proposed solutions include a combination of people, process and technology to improve organisations’ ability to respond to exploited or high-risk vulnerabilities in faster and more targeted ways, as opposed to trying to resolve all vulnerabilities. The paper proposes effective solutions organisations can use to improve their vulnerability remediation process and their ability to respond to exposures quickly, effectively and with measurable progress.

To assess the biocompatibility of a novel implant made of Nitinol (nickel-titanium alloy), designed to improve aqueous humor outflow. In the first arm of biocompatibility testing, microstents were surgically inserted into Schlemm's canal (SC) of 2 non-human primates (NHPs), and a third NHP served as a surgical sham control. After 13 weeks the animals were killed, and the eyes were examined by light and scanning electron microscopy. Two masked investigators evaluated the histology sections. The second arm utilized 8 New Zealand white rabbits; each rabbit received a microstent inserted into the sclera and subconjunctival space by means of passage across the anterior chamber thus providing contact with several representative ocular tissues. The fellow eye of each rabbit underwent a sham procedure without microstent insertion. The rabbits were killed after 26 weeks, and a trained ocular pathologist examined the specimens using light microscopy. Histologic and scanning electron microscopy analysis of the NHPs demonstrated that the microstents were located in SC. There was no evidence of an acute or chronic inflammatory response, granulation response, or fibrosis in the outflow system or in adjacent tissues. Rabbit eyes showed minimal mononuclear cell infiltration and minimal fibrotic responses at the site of the implants when compared with sham-treated control eyes. The Hydrus Microstent was associated with minimal inflammation in both NHP and rabbit eyes with extended follow-up. These preclinical studies demonstrate that the Hydrus Microstent appears to have excellent long-term biocompatibility.